While a new report from Goldman Sachs says health care is in a state of flux that most of the sector’s companies haven’t adjusted to yet, it also pinpoints four that have plenty of cash that could be put to good use for investo…
Sanofi-Aventis, which has been unsuccessful recently in its courtship of U.S. giant biotech Genzyme, announced another setback today. A late-stage trial of NV1FGF did not meet its primary goal of preventing a major amputation o…
Japanese electronics company Sharp is turning up the heat in the increasingly competitive solar energy market, announcing plans Wednesday to acquire solar energy producer Recurrent Energy in a cash deal worth upwards of $305 mi…
After a long wait, the FDA has OK’d Novartis’s Gilenya as a first-line treatment for relapsing forms of multiple sclerosis — the disease’s most common form. MS affects over 400,000 Americans and more than 2.1 million people wo…
Daimler AG (DDAIF) denied that is in talks with Fiat SpA (FIATY) about taking over the Italian carmaker’s industrial operations.
“There are no talks on this with Fiat,” Daimler spokesman Florian Martens told Bloomberg News. “In our industry at this t…